Hormonal
High circulating levels of the artificial sweetener erythritol are associated with a significantly increased risk of major adverse cardiovascular events (MACE), including heart attack and stroke, and directly enhance platelet reactivity and thrombosis potential.
If you consume erythritol (a common artificial sweetener in 'keto' products, sugar-free drinks, and baked goods), be aware that it can accumulate in your blood and make your platelets more likely to form clots. This risk is particularly relevant if you have existing heart disease, diabetes, or high blood pressure. While occasional use may not pose a significant risk for healthy individuals, those at higher cardiovascular risk should consider limiting erythritol intake and consulting their doctor, especially given that levels can remain elevated for days after consumption.
In both validation cohorts, plasma levels of erythritol were higher among individuals with prevalent CVD... higher levels of erythritol were also observed among those who experienced an incident MACE over the ensuing 3 years of follow-up... erythritol enhanced platelet reactivity in vitro and thrombosis formation in vivo.
Why this rating
Strong observational data across multiple large cohorts (n>4,000) combined with consistent in vitro and in vivo mechanistic evidence, though the intervention study was small (n=8).
Source
The artificial sweetener erythritol and cardiovascular event risk
Marco Witkowski et al. · Nature Medicine · 2023
DOI 10.1038/s41591-023-02223-9
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →